Concert Pharmaceuticals is expected to report top-line data from CTP-543 in patients with moderate-to-severe alopecia areata in Q4, Mizuho analyst Difei Yang tells investors in a research note. The analyst expects the readout will be an important catalyst for Concert shares and remains confident in the potential of CTP-543. The company is well positioned relative to most alopecia areata competitors from a timeline perspective, Yang contends. She keeps a Buy rating on Concert Pharmaceuticals with a $27 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.